Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial—Rationale and design

Hunt, 2009, Circulation, 119, e391, 10.1161/CIRCULATIONAHA.109.192065 McMurray, 2012, Eur J Heart Fail, 14, 803, 10.1093/eurjhf/hfs033 Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 Dimopoulos, 2004, Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a β-blocker), Int J Cardiol, 93, 105, 10.1016/j.ijcard.2003.10.001 McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3 Smith, 2005, Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan, Am J Cardiovasc Drugs, 5, 41, 10.2165/00129784-200505010-00006 Ichikawa, 2001, Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin–angiotensin–aldosterone system in hypertensive patients, Hypertens Res, 24, 641, 10.1291/hypres.24.641 Tsutamoto, 2010, Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension, Hypertens Res, 33, 118, 10.1038/hr.2009.192 Sezai, 2011, Effects of olmesartan on the renin–angiotensin–aldosterone system for patients with essential hypertension after cardiac surgery—investigation using a candesartan change-over study, Ann Thorac Cardiovasc Surg, 17, 487, 10.5761/atcs.oa.11.01691 Agata, 2006, Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme, Hypertens Res, 29, 865, 10.1291/hypres.29.865 Zou, 2004, Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II, Nat Cell Biol, 6, 499, 10.1038/ncb1137 Miura, 2006, Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor, J Biol Chem, 281, 19288, 10.1074/jbc.M602144200 Shiba, 2008, Emerging problems of heart failure practice in Japanese women: lessons from the CHART study, Circ J, 72, 2009, 10.1253/circj.CJ-07-1000 Nochioka, 2010, Both high and low body mass indexes are prognostic risks in Japanese patients with chronic heart failure: implications from the CHART study, J Card Fail, 16, 880, 10.1016/j.cardfail.2010.06.413 Chobanian, 2003, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Matsuzawa, 2004, Adiponectin and metabolic syndrome, Arterioscler Thromb Vasc Biol, 24, 29, 10.1161/01.ATV.0000099786.99623.EF Chen, 2012, Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome, PLoS One, 7, e45693, 10.1371/journal.pone.0045693 Matsubara, 2012, Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study, J Cardiol, 60, 389, 10.1016/j.jjcc.2012.07.012 Sakaguchi, 2012, Preliminary observations of passive exercise using whole body periodic acceleration on coronary microcirculation and glucose tolerance in patients with type 2 diabetes, J Cardiol, 60, 283, 10.1016/j.jjcc.2012.05.006 Ge, 2012, MicroRNAs regulated by adiponectin as novel targets for controlling adipose tissue inflammation, Endocrinology, 153, 5285, 10.1210/en.2012-1623 Karolina, 2012, Circulating miRNA profiles in patients with metabolic syndrome, J Clin Endocrinol Metab, 97, E2271, 10.1210/jc.2012-1996 Shiba, 2011, Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan. First report from the CHART-2 study, Circ J, 75, 823, 10.1253/circj.CJ-11-0135 Miura, 2012, Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study, Eur J Heart Fail, 14, 367, 10.1093/eurjhf/hfs001 Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7 Massie, 2008, Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 2456, 10.1056/NEJMoa0805450 Lund, 2012, Association between use of renin–angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction, JAMA, 308, 2108, 10.1001/jama.2012.14785 Anand, 2011, Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial, Circ Heart Fail, 4, 569, 10.1161/CIRCHEARTFAILURE.111.962654 Yasuda, 2008, Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation, EMBO Rep, 9, 179, 10.1038/sj.embor.7401157 Ogihara, 2008, Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial, Hypertension, 5, 393, 10.1161/HYPERTENSIONAHA.107.098475 Kasanuki, 2009, Eur Heart J, 30, 1203, 10.1093/eurheartj/ehp101 Muramatsu, 2012, Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study, Hypertension, 59, 580, 10.1161/HYPERTENSIONAHA.111.184226